主要甲状腺癌相关综合征的人群患病率
基于All of Us研究项目245394名和英国生物银行469558名参与者的横断面研究,从ClinVar数据库识别致病及可能致病变异,估算甲状腺癌相关综合征的患病率。MEN2、PHTS和FAP与甲状腺癌显著相关,MEN2和PHTS患病率约为目前一般人群估计值的10至20倍,多数受累个体未被诊断为甲状腺癌。
要点
- MEN2、PHTS和FAP与甲状腺癌显著相关(P值分别为3.23e-20、2.59e-15、2.73e-10)。
- All of Us中MEN2、PHTS、FAP患病率分别为1:2172、1:8764、1:8461。
- 英国生物银行中MEN2、PHTS、FAP患病率分别为1:2348、1:13043、1:8238。
核心结论
- MEN2和PHTS的患病率约为目前一般人群估计值的10至20倍。
- 多数受累个体未被诊断为甲状腺癌。
- 研究结果可能改变对中危RET突变患者的临床处理方式。
研究设计与样本
- 横断面研究,从ClinVar数据库识别致病及可能致病(P/LP)变异。
- 纳入All of Us研究项目245394名参与者和英国生物银行469558名参与者。
主要发现
- MEN2(RET基因,P=3.23e-20)、PHTS(PTEN基因,P=2.59e-15)和FAP(APC基因,P=2.73e-10)与甲状腺癌显著相关。
- All of Us中MEN2、PHTS、FAP患病率分别为1:2172、1:8764、1:8461。
- 英国生物银行中MEN2、PHTS、FAP患病率分别为1:2348、1:13043、1:8238。
- 导致2个氨基酸替换V804M和V804L的3种致病RET变异占All of Us中所有MEN2变异的65%,这些携带者均未被诊断为甲状腺癌。
关键数值与推荐
- MEN2、PHTS和FAP与甲状腺癌显著相关,P值分别为3.23e-20、2.59e-15和2.73e-10。
- All of Us中MEN2患病率为1:2172,PHTS为1:8764,FAP为1:8461。
- 英国生物银行中MEN2患病率为1:2348,PHTS为1:13043,FAP为1:8238。
- 导致V804M和V804L氨基酸替换的3种致病RET变异占All of Us中MEN2变异的65%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Understanding the population prevalence of thyroid cancer-associated syndromes is important to guide germline genetic testing and clinical management. OBJECTIVE: To estimate the prevalence of the major thyroid cancer-associated syndromes in the United States using data from the All of Us Research Program (All of Us) and the UK Biobank. METHODS: In this cross-sectional study, we identified pathogenic and likely pathogenic (P/LP) variants from the ClinVar database in 245 394 All of Us and 469 558 UK Biobank participants. We calculated the prevalence of thyroid cancer-associated syndromes defined by the presence of P/LP variants. RESULTS: Using logistic regression, we found that 3 hereditary syndromes, multiple endocrine neoplasia type 2 (MEN2, RET gene, P = 3.23e-20), PTEN hamartoma tumor syndrome (PHTS, PTEN gene, P = 2.59e-15), and familial adenomatous polyposis type 1 (FAP, APC gene, P = 2.73e-10) were significantly associated with thyroid cancer. The prevalence of thyroid cancer-associated syndromes in the All of Us was 1:2172, 1:8764, and 1:8461, and in the UK Biobank, it was 1:2348, 1:13 043, and 1:8238 for MEN2, PHTS, and FAP, respectively. Three pathogenic RET variants that cause 2 amino acid substitutions, V804M and V804L, constitute 65% of all MEN2 variants in the All of Us, and none of these carriers were diagnosed with thyroid cancer. CONCLUSION: The prevalence of MEN2 and PHTS is ∼10 to 20 times higher than is currently estimated for the general population. Most affected individuals are not diagnosed with thyroid cancer. Our findings may change the clinical approach to patients with moderate-risk RET mutations.
引用
- White SL, Jamil T, Bell C, et al. Population Prevalence of the Major Thyroid Cancer-Associated Syndromes. J Clin Endocrinol Metab. 2025. PMID: 40231587. doi:10.1210/clinem/dgaf236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。